Liver Cancer - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The liver cancer market size was valued at USD 15.05 billion in 2025 and estimated to grow from USD 17.55 billion in 2026 to reach USD 37.78 billion by 2031, at a CAGR of 16.60% during the forecast period (2026-2031). This report is Segmented by Cancer Type (Hepatocellular Carcinoma, Cholangiocarcinoma, and More), Therapy (Targeted Therapy, Chemotherapy, and More), Age Group (Adults, Geriatric, and Pediatric), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and More), and Geography (North America, Europe, Asia-Pacific and More). The Market and Forecasts are Provided in Terms of Value (USD).

Global Liver Cancer Market Trends and Insights

Surge in Incidence of Hepatocellular Carcinoma (HCC)

Global hepatocellular carcinoma cases are projected to increase by 53.8%, from 905,347 in 2020 to 1,392,474 by 2040, underscoring the long-term demand for treatment solutions. Asia-Pacific shoulders roughly three-quarters of chronic hepatitis B infections, while Mongolia registers the world’s highest age-standardized incidence. Rising metabolic dysfunction-associated steatotic liver disease (MASLD) in high-income economies adds a second growth pillar as obesity-linked HCC cases escalate, especially among younger cohorts in Northern Europe and parts of Asia. These epidemiologic shifts ensure durable expansion of the liver cancer market, reinforced by ageing populations and extended life expectancy in China, Japan, and Western Europe

Expanding First-Line Approvals of Drug Combos

The April 2025 FDA approval of nivolumab plus ipilimumab reset global first-line standards, yielding a 23.7-month median overall survival versus 20.6 months for sorafenib or lenvatinib monotherapy. Europe ratified the regimen two months later, triggering rapid guideline updates across national health systems. Positive EMERALD-1 and LEAP-012 readouts further validated integrating checkpoint inhibitors with anti-VEGF or locoregional treatments, lifting adoption curves and accelerating payer assessments. As reimbursement frameworks adapt, premium-priced combinations enlarge revenue pools and intensify R&D competition.

Severe Immune-Related Adverse Events (irAEs) in Cirrhotics

Checkpoint inhibitor hepatotoxicity appears in 12.9% of cirrhotic patients, prompting 18% discontinuation in the nivolumab-ipilimumab arm of CheckMate-9DW. Geriatric cohorts show heightened vulnerability, necessitating biomarkers that predict irAE risk to maintain treatment uptake.

Other drivers and restraints analyzed in the detailed report include:

• Rapid NAFLD and NASH Conversion into HCC in Obese Cohorts
• Wider Reimbursement for Loco-Regional TACE-IO Protocols
• High Attrition in Late-Phase Trials

Segment Analysis

Hepatocellular carcinoma secured a 74.88% market share in the liver cancer market in 2025, validating its role as the primary value driver. This dominance reflects both incidence rates and the weight of R&D capital directed toward checkpoint combinations and anti-angiogenic backbones. The April 2025 dual-checkpoint approval intensified competitive differentiation and expanded frontline choices. Cholangiocarcinoma remains a minor but strategically important niche where fast-track designations for tumor-infiltrating lymphocyte products illustrate regulatory appetite for cell-based innovation.

Hepatoblastoma, though rare, is advancing at a 19.18% CAGR, buoyed by improved imaging and molecular profiling that allow early surgical candidacy and enrollment in pediatric immunotherapy trials. Gene-expression studies are propelling precision dosing, and CAR-T exploration for pediatric solid tumors is introducing potentially curative options. This tail-segment acceleration diversifies revenue sources and spurs partnerships with academic centers specializing in pediatric oncology.

Chemotherapy retained 30.72% of the liver cancer market share in 2025, due to its widespread availability and low acquisition cost, especially in resource-constrained regions. Yet, targeted therapy is growing at a 19.25% CAGR as oncologists prioritize precision over cytotoxicity. Atezolizumab-bevacizumab and durvalumab-bevacizumab combinations demonstrate sustained progression-free benefits, supporting expanded indications in guidelines. Radiopharmaceuticals, including actinium-225 constructs from RayzeBio, broaden the targeted spectrum with highly localized alpha-particle lethality.

Immunotherapy’s rise drives the shift toward multimodal regimens that integrate stereotactic radiation and transarterial procedures, enabling deeper responses while sparing healthy parenchyma. Chemotherapy now primarily features in combination schedules or as bridging therapy awaiting the initiation of immuno-targeted therapy.

Complete Report Scope:

• By Cancer Type
  • Hepatocellular Carcinoma
  • Cholangiocarcinoma
  • Hepatoblastoma
  • Other Primary Liver Cancers
• By Product Type
  • Therapy
    • Targeted Therapy
    • Immunotherapy
    • Chemotherapy
    • Radiation Therapy
  • Diagnostic
    • Ultrasound Scans
    • Confirmatory Needle Biopsy
    • Endoscopic Ultrasound
    • CT Scan
    • PET Scan
    • Other Diagnostic Types
• By Age Group
  • Adults
  • Geriatric
  • Pediatric
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America commanded 39.68% of global revenue in 2025, buoyed by early checkpoint inhibitor uptake, generous insurance coverage, and leading clinical-trial density. FDA’s Project Orbis fosters simultaneous multinational review, accelerating first-in-class access for United States patients and partners in Canada and Australia. Inflation Reduction Act price-negotiation provisions, however, may curb list-price growth, encouraging companies to optimize launch sequencing.

Asia-Pacific is projected to post a 19.02% CAGR through 2031, the fastest worldwide. China, holding more than 50% of incident cases, blends steep NRDL price reductions with rising urban insurance penetration, which expands volume to offset constrained margins. Japan and South Korea supply robust investigator networks, with roughly half of global HCC trials enrolling at Asia-Pacific sites, reducing development timelines.

Europe maintains consistent uptake supported by centralized health-technology assessments and pathway harmonization. EMA’s endorsement of dual-checkpoint regimens streamlines regional reimbursement. Latin America and the Middle East deliver emerging upside as public-private partnerships expand radiotherapy capacity and viral-hepatitis elimination drives surveillance.

List of Companies Covered in this Report:

• Roche
• Bayer
• Bristol-Myers Squibb
• Merck
• Pfizer
• AstraZeneca
• Eli Lilly and Company
• Novartis
• Abbvie
• Amgen
• Johnson & Johnson
• Eisai
• Exelixis
• Celsion (Imunon)
• Sanofi
• Gilead Sciences
• BeiGene
• Innovent Biologics
• Sumitomo Pharma
• Hepion Pharmaceuticals
• Abbott Laboratories
• Boston Scientific
• Siemens Healthineers

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support